BioSpace News Archive

Datavant, the leader in helping healthcare organizations safely connect their data while protecting patient privacy, announced the acquisition of Highland Math as well as the release of its Connect Cloud product suite.

Tempo Automation, the leading software-enabled manufacturer for quick-turn prototyping and low-volume production of printed circuit board assemblies (“PCBA”), today announces that Ryan Benton has joined the management team as its Chief Financial Officer reporting to Tempo Automation’s Chief Executive Officer, Joy Weiss.

Brown Gibbons Lang & Company (“BGL”) is pleased to announce the simultaneous recapitalizations of Grandview Surgery Center and North East Surgery Center (“NESC”) by Surgical Care Affiliates (“SCA”) and Geisinger Health, respectively.

Cannformatics , an early stage biotech startup focused on personalizing medical cannabis treatments through the identification and application of cannabis - responsive ™ biomarkers found

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the status of patient enrollment in its phase 3 dry eye clinical trial (ARISE-3). http://www.regenerx.com/2020-08-19-August-1

Healthcare company Scope Eyecare enters the Texas market this week with its OPTASE® dry eye treatment products arriving on the shelves of the iconic Texas retailer H-E-B.

Shareholders meeting is set for Aug 31st, 2020. The proxy includes proposals for a reverse stock split and authorizing additional shares of capital stock.

Elekta (EKTA-B.ST) announced today that its Geneva Universal Gynecological Applicator recently received U.S. FDA 510(k) clearance, enabling individuals with cervical cancer in the United States to benefit from the applicato

The percentage of people with chronic health conditions who feel concerned about COVID-19 has risen again to early pandemic levels, according to findings from a new Health Union survey.

Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on